Telomir Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bay Shore Trust, was filed 15 Feb 2024.
Telomir Pharmaceuticals, Inc.: what insiders have been doing
Telomir Pharmaceuticals, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). 1 insider has disclosed 1 filing since 22 October 2025.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
There has been no open-market purchase by an insider of Telomir Pharmaceuticals, Inc. for at least a year.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 1 filing, this issuer sits below that mark. Looking back to 2024, when coverage begins, insiders filed 2 purchases and no sales.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Since the insiders bought
- -56.5%Entry US$9.02 · Close at T+365 US$3.92
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 7,319,710 shares@ US$1.3711.46% mcap100.0% of flowCommon StockSEC:0001493152-26-018911:0
- 40,000 shares@ US$7.0044.9% of flowCommon StockSEC:0000897069-24-000395:1Canonical exit: 13 May 2024 (T+90)
- 49,000 shares@ US$7.00100.0% of flowCommon StockSEC:0000897069-24-000395:0Canonical exit: 13 May 2024 (T+90)
3 of 3 declarations
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. is a pharmaceutical company focused on developing innovative treatments based on telomere biology. It is listed on NASDAQ under the ticker XNAS.
